<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083834</url>
  </required_header>
  <id_info>
    <org_study_id>0006-17-BNZ</org_study_id>
    <nct_id>NCT03083834</nct_id>
  </id_info>
  <brief_title>Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients</brief_title>
  <official_title>Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bnai Zion Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bnai Zion Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In mitotane treated patients, serum cortisol cannot be used to diagnose hypoadrenalism, since
      mitotane increases cortisol binding globulin levels (CBG), artificially raising total
      cortisol. Salivary free cortisol (SC) is not affected by CBG alterations, and reflects the
      free serum cortisol.

      In the current study, investigators will assess serum and SC responses during low-dose
      cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on
      steroid replacement therapy and in patients who suffer from hypoadrenlism caused from other
      etiology. Investigators will compare results between groups and try to demonstrate the
      superiority of SC in assessing adrenal function in mitotane treated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80-90% of circulating cortisol is bound to cortisol binding globulin (CBG) or transcortin,
      whereas only 3-10% is in the free state. Salivary free cortisol (SC) is an index of plasma
      free cortisol. In previous studies it was shown that in low-dose cosyntropin stimulation
      test, SC increases significantly in normal but not in hypoadrenal patients. It was suggested
      that dynamic assessment of the SC response to ACTH may be particularly helpful whenever the
      measurement of serum cortisol is complicated by increased or decreased CBG levels.

      Adrenocortical carcinoma (ACC) is a rare malignancy with a heterogeneous presentation and a
      variable but generally poor prognosis. Mitotane is the main drug for ACC treatment and it
      plays a role both in adjuvant treatment after complete resection and in recurrent, inoperable
      and/or metastatic ACC. Mitotane blocks adrenocortical steroid synthesis and also exerts a
      specific cytotoxic effect on adrenocortical cells. Mitotane induces adrenal insufficiency,
      requiring hydrocortisone replacement therapy. In mitotane treated patients, serum cortisol
      cannot be used to diagnose hypoadrenalism, since mitotane increases CBG levels, artificially
      raising total cortisol. SC is not affected by CBG alterations, and reflects the free serum
      cortisol and may be more accurate in diagnosing hypoadrenalism in mitotane treated patients.

      In the current study, investigators will assess serum and SC responses during low-dose
      cosyntropin stimulation test in healthy volunteers, mitotane-induced hypoadrenal patients on
      steroid replacement therapy and in patients who suffer from hypoadrenlism caused from any
      other etiology. Investigators will compare results between groups and try to demonstrate the
      superiority of SC in assessing adrenal function in mitotane treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salivary free cortisol</measure>
    <time_frame>1 day</time_frame>
    <description>Salivary free cortisol concentrations during intravenous low dose cosyntropin stimulation test..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum cortisol</measure>
    <time_frame>1 day</time_frame>
    <description>Serum cortisol concentrations during intravenous low dose cosyntropin stimulation test.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Adrenal Insufficiency</condition>
  <condition>Adrenal Cancer</condition>
  <arm_group>
    <arm_group_label>healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose cosyntropin stimulation test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypoadrenal mitotane treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose cosyntropin stimulation test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypoadrenal no-mitotane treated patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose cosyntropin stimulation test</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cosyntropin stimulation test</intervention_name>
    <description>At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 Î¼g/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.</description>
    <arm_group_label>healthy subjects</arm_group_label>
    <arm_group_label>hypoadrenal mitotane treated patients</arm_group_label>
    <arm_group_label>hypoadrenal no-mitotane treated patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mitotane treated

          -  known hypoadrenlism

        Exclusion Criteria:

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Saiegh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai Zion Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leonard Saiegh, MD</last_name>
    <phone>+972506267262</phone>
    <email>leonard.saiegh@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bnai Zion MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Saiegh</last_name>
      <phone>506267262</phone>
      <email>leonard.saiegh@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Michal Yeiches</last_name>
      <phone>0528283062</phone>
      <email>yeiches@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bnai Zion Medical Center</investigator_affiliation>
    <investigator_full_name>leonard.saiegh</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cosyntropin</keyword>
  <keyword>salivary free cortisol</keyword>
  <keyword>mitotane</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Cosyntropin</mesh_term>
    <mesh_term>Mitotane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

